These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 34852093)

  • 1. Methods to evaluate COVID-19 vaccine effectiveness, with an emphasis on quasi-experimental approaches.
    Pescarini JM; Teixeira CSS; Cruz EP; Ortelan N; Pinto PFPS; Ferreira AJF; Alves FJO; Pinto Junior EP; Falcão IR; Rocha ADS; Silva NBD; Ortiz RF; Saavedra RDC; Oliveira VA; Ribeiro-Silva RC; Ichihara MYT; Boaventura V; Barral Netto M; Kerr LRFS; Werneck GL; Barreto ML
    Cien Saude Colet; 2021 Nov; 26(11):5599-5614. PubMed ID: 34852093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.
    Liu Q; Qin C; Liu M; Liu J
    Infect Dis Poverty; 2021 Nov; 10(1):132. PubMed ID: 34776011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of methodological approaches for evaluating real-world effectiveness of COVID-19 vaccines: Advising resource-constrained settings.
    Teerawattananon Y; Anothaisintawee T; Pheerapanyawaranun C; Botwright S; Akksilp K; Sirichumroonwit N; Budtarad N; Isaranuwatchai W
    PLoS One; 2022; 17(1):e0261930. PubMed ID: 35015761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines.
    Lewnard JA; Patel MM; Jewell NP; Verani JR; Kobayashi M; Tenforde MW; Dean NE; Cowling BJ; Lopman BA
    Epidemiology; 2021 Jul; 32(4):508-517. PubMed ID: 34001753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Need for a Practical Approach to Evaluate the Effectiveness of COVID-19 Vaccines for Low- and Middle-Income Countries.
    Nsanzimana S; Gupta A; Uwizihiwe JP; Haggstrom J; Dron L; Arora P; Park JJH
    Am J Trop Med Hyg; 2021 Jul; 105(3):561-563. PubMed ID: 34270458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccine trials: The potential for "hybrid" analyses.
    Fleming TR; Nason M; Krause PR; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Aug; 18(4):391-397. PubMed ID: 34041932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.
    Chung H; He S; Nasreen S; Sundaram ME; Buchan SA; Wilson SE; Chen B; Calzavara A; Fell DB; Austin PC; Wilson K; Schwartz KL; Brown KA; Gubbay JB; Basta NE; Mahmud SM; Righolt CH; Svenson LW; MacDonald SE; Janjua NZ; Tadrous M; Kwong JC;
    BMJ; 2021 Aug; 374():n1943. PubMed ID: 34417165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
    Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
    Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.
    Patel MK; Bergeri I; Bresee JS; Cowling BJ; Crowcroft NS; Fahmy K; Hirve S; Kang G; Katz MA; Lanata CF; L'Azou Jackson M; Joshi S; Lipsitch M; Mwenda JM; Nogareda F; Orenstein WA; Ortiz JR; Pebody R; Schrag SJ; Smith PG; Srikantiah P; Subissi L; Valenciano M; Vaughn DW; Verani JR; Wilder-Smith A; Feikin DR
    Vaccine; 2021 Jul; 39(30):4013-4024. PubMed ID: 34119350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
    Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding perception and acceptance of Sinopharm vaccine and vaccination against COVID-19 in the UAE.
    Ahamed F; Ganesan S; James A; Zaher WA
    BMC Public Health; 2021 Aug; 21(1):1602. PubMed ID: 34461846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
    Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
    Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic.
    Brehm TT; Thompson M; Ullrich F; Schwinge D; Addo MM; Spier A; Knobloch JK; Aepfelbacher M; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
    Int J Hyg Environ Health; 2021 Sep; 238():113851. PubMed ID: 34601375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of mRNA vaccines in curtailing SARS-CoV-2 infection and disability leave utilisation among healthcare workers during the COVID-19 pandemic: cross-sectional analysis from a tertiary healthcare system in the Greater Houston metropolitan area.
    Vahidy FS; Pan AP; Hagan K; Bako AT; Sostman HD; Schwartz RL; Phillips R; Boom ML
    BMJ Open; 2021 Oct; 11(10):e054332. PubMed ID: 34642201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.